REGN34
R$75.60
0.00%
Stock
Regeneron Pharmaceuticals, Inc.
Official Company Name: Regeneron Pharmaceuticals, Inc.
Stock Symbol: REGN34
Stock Market: B3 - Bovespa
Currency: Brazilian real - BRL
REGN34 Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▲+16.59%
Daily closing prices, with moving averages and volumes - Brazilian real (BRL)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Regeneron Pharmaceuticals, Inc. Categories
United States
languages
Healthcare
languages
Biotechnology
Healthcare
Biotechnology
Company Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company dedicated to molecules signaling, and targeted antibody drugs. Thanks to its patented treatments and technologies, Regeneron provides remedies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases, and rare diseases.
REGN34 Stock Data
| Open | R$75.60 |
| High | R$75.60 |
| Low | R$75.60 |
| Close | R$75.60 |
| Volume | 0 |
| Previous Close | R$75.60 |
| 1-Day Change | 0.00 |
| 1-Year Change | 10.76 |
| Average Daily Volume | 360 |
| 52-Week High | R$111.72 |
| 52-Week Low | R$64.84 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.